Previous 10 | Next 10 |
SELLAS Life Sciences (NASDAQ: SLS ) +20% on positive analyst action . More news on: SELLAS Life Sciences Group, Inc., Attunity Ltd, Floor & Decor Holdings, Inc., Stocks on the move, , Top stock market news, Read more ...
Thinly traded nano cap Moleculin Biotech (NASDAQ: MBRX ) is up 12% premarket on modestly higher volume in reaction to its announcement of encouraging results from a Phase 1 study of WP1066. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, ...
November 1, 2018 Palm Beach, FL – (November 1, 2018) – Multiple myeloma (MM) known as a plasma cell malignancy that affects 14,000 patients per year are fueling the development and clinical activities for new therapies to treat these malignancies. Recent clinical trial resu...
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candida...
Thinly traded nano cap Moleculin Biotech (NASDAQ: MBRX ) is up 27% premarket, albeit on only 990 shares, following its announcement of preclinical data on WP1066 that support its potential use in pediatric brain tumors. More news on: Moleculin Biotech, Inc., Healthcare stocks...
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System...
Moleculin Biotech (NASDAQ: MBRX ) has initiated a Phase 1 clinical trial of a new cancer drug candidate, a small molecule compound discovered by Prof. Waldemar Priebe at The University of Texas MD Anderson Cancer Center and known as WP1066. More news on: Moleculin Biotech, Inc., Hea...
September 13, 2018 Palm Beach, FL – (September 13, 2018) – Biotech and Big Pharma stocks have been performing very well of lat as the SPDR S&P Pharmaceuticals ETF has risen just about 15% since the beginning of 2018, compared with 8.5% gains for the S&P 500, and up ...
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- In the ongoing challenge to combat the almos...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $109.21 on volume of 508,402,989 shares Redhill Biopharma Ltd. (RDHL) rose 97.9% to $0.76 on volume of 355,380,053 shares PROSHARES TRUST (SQQQ) rose 7.3% to $9.22 on volume of 284,777,109 shares ...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...